Elena G. Chiorean
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

Dr. Elena G. Chiorean

Hematology Oncology | Hematology | Oncology
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elena Chiorean is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Chiorean is rated as an Advanced provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Chiorean is currently accepting new patients.

Her clinical research consists of co-authoring 108 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Armenian
Filipino
Japanese
Romanian
Spanish
Vietnamese
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195
Other Locations
THE ASSOCIATION OF UNIVERSITY PHYSICIANS
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Enrollment Status: Completed
Publish Date: June 18, 2025
Intervention Type: Other, Drug
Study Drugs: Clobetasol propionate, Regorafenib
Study Phase: Phase 2
Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR Tᴍsʟɴ) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Phase I Study of Autologous Transgenic T-Cells Expressing High Affinity Mesothelin-Specific T-Cell Receptor (TCR) (FH-TCR Tᴍsʟɴ) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Terminated
Publish Date: April 20, 2025
Intervention Type: Drug, Biological
Study Drugs: Autologous Mesothelin-specific TCR-T Cells, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies
Enrollment Status: Available
Publish Date: September 23, 2024
Intervention Type: Drug
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drugs: PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
Study Phase: Phase 1/Phase 2
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers
Enrollment Status: Completed
Publish Date: June 07, 2022
Intervention Type: Drug, Other
Study Drugs: Afatinib, Capecitabine
Study Phase: Phase 1
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Enrollment Status: Terminated
Publish Date: May 06, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 10 Less Clinical Trials

108 Total Publications

LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes.
LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes.
Journal: JCO precision oncology
Published: July 09, 2025
Similar Doctors
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Shih-li B. Lin
Hematology Oncology | Hematology
Distinguished in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Shih-li B. Lin
Hematology Oncology | Hematology

Virginia Mason Medical Center

33501 1st Way S, 
Federal Way, WA 
 (24.1 miles away)
253-838-2400
Languages Spoken:
English, German, Hindi, Korean, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Shih-li Lin is a Hematologist Oncology specialist and a Hematologist in Federal Way, Washington. Dr. Lin is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Ampullary Cancer, Anal Cancer, and Lynch Syndrome. Dr. Lin is currently accepting new patients.

Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Jorge M. Chaves
Hematology Oncology | Hematology | Oncology
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Jorge M. Chaves
Hematology Oncology | Hematology | Oncology

Northwest Medical Specialties PLLC

1624 S I St, Suite 305, 
Tacoma, WA 
 (28.6 miles away)
253-428-8700
Languages Spoken:
English, Castilian, Filipino, Konkani, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jorge Chaves is a Hematologist Oncology specialist and a Hematologist in Tacoma, Washington. Dr. Chaves is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Dehydration, and Lynch Syndrome. Dr. Chaves is currently accepting new patients.

Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Francis M. Senecal
Hematology Oncology | Hematology | Oncology
Advanced in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Dr. Francis M. Senecal
Hematology Oncology | Hematology | Oncology

Northwest Medical Specialties PLLC

11511 Canterwood Blvd, Suite 45, 
Gig Harbor, WA 
 (24.4 miles away)
253-428-8700
Languages Spoken:
English, Castilian, Dutch, Konkani, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Francis Senecal is a Hematologist Oncology specialist and a Hematologist in Gig Harbor, Washington. Dr. Senecal is rated as a Distinguished provider by MediFind in the treatment of Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET). His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, Inflammatory Breast Cancer, and Bone Marrow Aspiration. Dr. Senecal is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chiorean's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile